SARA FRANKE: Open Payments
NPI 1952040651 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$483 in 20 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $216 · 2025 $483
Food & beverage: $483
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $106 |
| Novo Nordisk Inc | 3 | $83 |
| Merck Sharp & Dohme LLC | 3 | $74 |
| PFIZER INC. | 3 | $70 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 1 | $25 |
Products named: Wegovy, LEQVIO, VERQUVO, VYNDAQEL, WAINUA, Kerendia, JARDIANCE, ENTRESTO.
Industry payments across CT — which companies pay providers there.
